New data put Lundbeck firmly on GSK's tail in 5HT6 inhibitor Alzheimer's race
This article was originally published in Scrip
Executive Summary
Lundbeck's novel selective 5HT6 receptor inhibitor Lu AE58054 may have fallen at the Phase II hurdle in schizophrenia, but the company seems to be reaping the rewards of pursuing its development in the notoriously difficult indication of Alzheimer's disease.